test

Joseph W Kim MD

Assistant Professor of Medicine (Medical Oncology)

Clinical Interests

Prostate cancer, bladder cancer, immunotherapy, early drug development


Board Certifications

 
Hematology, Internal Medicine, Board Eligible
2010
Internal Medicine, Board Certified
2013
Medical Oncology, Board Certified

Patient Care Locations

 
joseph_w_kimfaculty-clinicsfalsetruetrue6truefalsefalse
 

Clinical Trials

Conditions Study Title
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and Stomach A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Bladder, Breast - Female, Lung, Pancreas, and Stomach A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Lymphoid Leukemia A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients with Advanced Cancers
Prostate A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF SIPULEUCEL-T WITH CONCURRENT VERSUS SEQUENTIAL ADMINISTRATION OF ENZALUTAMIDE IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Breast - Female, Colon, Lung, Melanoma, skin, Ovary, Rectum, and Stomach A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

More Clinical Trials...

Edit Profile